Keith Adrian Powell

Domainex Ltd. operates as a drug discovery company. Its services include drug target expression, structural biology, virtual hit screening, medicinal chemistry, computational chemistry, assay development, and fragment based screening. The firm offers combinatorial domain hunting technology, and leadbuilder virtual hit screening software. The company was founded by Laurence Harris Pearl, Renos Savva, Paul Driscoll and Chrisostosmos Prodromou in 2001 and is headquartered in Saffron Walden, the United Kingdom.

PolyTherics Ltd. develops biomedical polymers for therapeutic applications. The company was founded by Antony Godwin, Sunil Shaunak and Steve Brocchini in 2001 and is headquartered in Babraham, the United Kingdom.

Genex has developed the world's most efficient vector system (LipTide) for delivery of DNA, RNA and drugs into cells for gene expression, gene knockdown and drug therapy. LipTide technology is available for licensing to companies developing DNA or RNA based therapies. The company was founded in 2002 and is headquartered in London, GB.

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Longbow Capital LLP (Longbow Capital) is a private equity firm founded in 2004 by Jonathan Powell, Edward Beckett, Robin Finlayson, Kevin Doyle, Colin Bothway, Ron Petersen and Edward Rudd. The firm is headquartered in Norwich, United Kingdom.

Part of AstraZeneca PLC, Zeneca Garden Care is a British company that develops and manufactures pharmaceutical products, agrochemicals, and specialty chemicals. The company is based in Macclesfield, UK. Zeneca Garden Care was acquired by Zeneca Group Plc on January 01, 1995 for $84.16 million.

Pharmidex Pharmaceutical Services Ltd. develops medicines for central nervous system diseases. Its offers In Vitro Admet, Cerense-drug delivery, Bioanalysis and Metabolism, CNS solution, Biomaging, Pharmacokinetics, Physicochemical properties and Zebrafish. The company was founded by Alan Palmer and Mohammad Sadeghi Alavijeh in 2002 and is headquartered in London, the United Kingdom.

Canbex Therapeutics Ltd. engages in the development of novel peripherally-acting cannabinoid agonists and mimetics for the treatment of multiple sclerosis spasticity and pain. Its lead drug candidate, VSN 16, has been established as a potent, stable and orally-available agonist of GPR-55 with a clear anti-spasticity effect in a validated preclinical model. The company was founded by David Baker, Gavin Giovannoni, Cristina Visintin, Gareth Pryce and David Lawrence Selwood in 2005 and is headquartered in London, the United Kingdom.